Brief: Elicera Therapeutics Q1 Adj. EPS at SEK -0.11
May 16 (Reuters) - Elicera Therapeutics Q1 adjusted EPS SEK -0.11. * Q1 loss for the period SEK -2.3 million * Q1 operating loss SEK -2.3 million * Q1 cash flow from operating activities SEK -2.04 million
Recent news on Elicera Therapeutics AB
See all newsBrief: Elicera Therapeutics Completes Phase I Part Of Carma Study
Brief: Elicera Therapeutics Gets Medical Products Agency Approval To Advance CARMA Study
Brief: Elicera Gets Clearance To Use Highest ELC-301 Dose Ahead Of Phase IIa
Brief: Elicera Gets First Patent Allowance For ELC-201
Brief: Elicera Receives Notice Of Allowance For U.S. Patent Application